Product Description
Clopidogrel is used alone or with aspirin to prevent serious or life-threatening problems with the heart and blood vessels in people who have had a stroke, heart attack, or severe chest pain. This includes people who have percutaneous coronary intervention (PCI; angioplasty; a type of heart surgery) that may involve inserting coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow) or who have coronary artery bypass grafting (CABG; a type of heart surgery). Clopidogrel is also used to prevent serious or life-threatening problems with the heart and blood vessels in people who have peripheral arterial disease (poor circulation in the blood vessels that supply blood to the legs). Clopidogrel is in a class of medications called antiplatelet medications. It works by preventing platelets (a type of blood cell) from collecting and forming clots that may cause a heart attack or stroke. (Sourced from: https://medlineplus.gov/druginfo/meds/a601040.html)
Mechanisms of Action: P2Y12 Antagonist,GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Nepal, Netherlands, New Zealand, Norway, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 19
Highest Development Phases
Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Ischemic Stroke|Pneumonia|Scleroderma, Diffuse|Scleroderma, General|Scleroderma, Systemic|Thrombosis
Phase 2: Atrial Fibrillation|Ischemic Attack, Transient|Stroke
Phase 1: Acute Coronary Syndrome|Angina, Stable|Angina, Unstable|Blood Platelet Disorders|Chronic Pain|Coronary Disease|Epilepsy|Healthy Volunteers|Myocardial Infarction|Oncology Solid Tumor Unspecified|Peripheral Arterial Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507015-35-00 | P3 |
Unknown Status |
Coronary Artery Disease |
2031-02-28 |
|
| PSSIT | P3 |
Recruiting |
Scleroderma, General|Scleroderma, Systemic|Scleroderma, Diffuse |
2030-06-01 |
|
| ANGIODAPT | P3 |
Active, not recruiting |
Coronary Artery Disease |
2029-07-21 |
|
| ANDES | P3 |
Active, not recruiting |
Thrombosis|Ischemic Stroke |
2026-07-18 |